This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Salud financiera de hoja de balance de Forma Therapeutics Holdings
Salud financiera controles de criterios 6/6
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$395.90m |
| Patrimonio | US$414.49m |
| Total pasivo | US$60.68m |
| Activos totales | US$475.17m |
Actualizaciones recientes sobre salud financiera
We're Keeping An Eye On Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Rate
Aug 30
We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Mar 04We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Nov 20Here's Why We're Not Too Worried About Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Situation
Aug 13We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Needs To Drive Business Growth Carefully
Apr 18Recent updates
We're Keeping An Eye On Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Rate
Aug 30Forma Therapeutics GAAP EPS of -$1.10 misses by $0.11
Aug 05We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Mar 04We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Nov 20Here's Why We're Not Too Worried About Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Situation
Aug 13We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Needs To Drive Business Growth Carefully
Apr 18What Type Of Shareholders Own The Most Number of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Shares?
Jan 03Forma Therapeutics closes public offering priced at $45.25
Dec 16Forma Therapeutics prices equity offering at $45.25
Dec 11Forma Therapeutics' sickle cell treatment shows promising action at ASH presentation
Dec 08Forma Therapeutics EPS beats by $0.01
Nov 12Forma Therapeutics' sickle cell candidate an orphan drug in Europe
Nov 10Análisis de la situación financiera
Pasivos a corto plazo: FMTX's short term assets ($426.4M) exceed its short term liabilities ($33.5M).
Pasivo a largo plazo: FMTX's short term assets ($426.4M) exceed its long term liabilities ($27.2M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: FMTX is debt free.
Reducción de la deuda: FMTX has not had any debt for past 5 years.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: FMTX has sufficient cash runway for more than a year based on its current free cash flow.
Pronóstico de cash runway: FMTX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 18.9% each year.